Laboratory of General Surgery, Department of Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, PR China.
Oncol Rep. 2012 Jan;27(1):265-9. doi: 10.3892/or.2011.1475. Epub 2011 Sep 28.
We investigated the relationship of ABCB1/MDR1, ABCC1/MRP1 and ABCG2/BCRP expression and promoter methylation with pancreatic cancer tumorigenesis and drug resistance. Gemcitabine-resistant pancreatic cancer cells, SW1990/GZ (33.3-fold increased resistance), were obtained by treating SW1990 cells with gemcitabine. The expression of ABCB1/MDR1, ABCC1/MRP1 and ABCG2/BCRP was determined by quantitative real-time RT-PCR in the cell lines, 3 normal pancreatic tissues, 15 human pancreatic cancer samples and 15 adjacent tissues. Promoter methylation was determined in cell lines by bisulfite genomic sequencing. ABCB1/MDR1, ABCC1/MRP1 and ABCG2/BCRP were upregulated in SW1990 and SW1990/GZ compared with normal pancreatic tissue, and expression in SW1990/GZ was significantly higher than in SW1990 cells. ABCB1/MDR1, ABCC1/MRP1 and ABCG2/BCRP were upregulated in pancreatic cancer tissues, compared to adjacent tissues. The ABCB1/MDR1, ABCC1/MRP1 and ABCG2/BCRP promoter were hypomethylated in all the cell lines. ABCB1/MDR1, ABCC1/MRP1 and ABCG2/BCRP expression correlated with pancreatic cancer tumorigenesis and drug resistance in a mechanism that is independent of promoter methylation.
我们研究了 ABCB1/MDR1、ABCC1/MRP1 和 ABCG2/BCRP 的表达和启动子甲基化与胰腺癌发生和耐药的关系。通过用吉西他滨处理 SW1990 细胞,获得了对吉西他滨耐药的胰腺癌细胞系 SW1990/GZ(耐药性增加了 33.3 倍)。通过定量实时 RT-PCR 在细胞系、3 个正常胰腺组织、15 个人胰腺癌样本和 15 个相邻组织中测定了 ABCB1/MDR1、ABCC1/MRP1 和 ABCG2/BCRP 的表达。通过亚硫酸氢盐基因组测序在细胞系中测定了启动子甲基化。与正常胰腺组织相比,ABCB1/MDR1、ABCC1/MRP1 和 ABCG2/BCRP 在 SW1990 和 SW1990/GZ 中上调,并且 SW1990/GZ 中的表达明显高于 SW1990 细胞。与相邻组织相比,ABCB1/MDR1、ABCC1/MRP1 和 ABCG2/BCRP 在胰腺癌组织中上调。ABCB1/MDR1、ABCC1/MRP1 和 ABCG2/BCRP 的启动子在所有细胞系中均呈低甲基化状态。ABCB1/MDR1、ABCC1/MRP1 和 ABCG2/BCRP 的表达与胰腺癌的发生和耐药相关,这种相关性与启动子甲基化无关。